,
Rodríguez-Quiroga, A.
Flamarique, I.
Castro-Fornieles, J.
Lievesley, K.
Buitelaar, J. K.
Coghill, D.
Díaz-Caneja, C. M.
Dittmann, R. W.
Gupta, A.
Hoekstra, P. J.
Kehrmann, L.
Llorente, C.
Purper-Ouakil, D.
Schulze, U. M. E.
Zuddas, A.
Sala, R.
Singh, J.
Fiori, F.
Arango, C.
Santosh, Paramala http://orcid.org/0000-0003-4830-5893
Funding for this research was provided by:
FP7 Health (261411)
Instituto de Salud Carlos III ((S2010/BMD-2422 AGES))
Fundación Alicia Koplowitz
Fundación Mutua Madrileña
Article History
Received: 26 April 2018
Accepted: 1 April 2019
First Online: 3 May 2019
Compliance with ethical standards
:
: Professor Paramala Santosh is Director & CEO and stockholder in HealthTracker Ltd. Dr. F. Fiori is Chief Technology Officer employed by HealthTracker Ltd. Dr. K. Lievesley is a Programme Manager employed at HealthTracker Ltd. Dr. Rodríguez-Quiroga has previously held a Río Hortega grant, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness. Dr. Díaz-Caneja has previously held a Río Hortega grant, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, and a Grant from Fundación Alicia Koplowitz. Dr. Dittmann has received compensation for serving as consultant or speaker, or he or the institution he works for have received research support or royalties from the organizations or companies indicated: EU (FP7 Programme), US National Institute of Mental Health (NIMH), German Federal Ministry of Health/Regulatory Agency (BMG/BfArM), German Federal Ministry of Education and Research (BMBF), German Research Foundation (DFG), Volkswagen Foundation; Boehringer Ingelheim, Ferring, Janssen-Cilag, Lilly, Lundbeck, Otsuka, Servier, Shire, Sunovion/Takeda, and Theravance. Dr. Dittmann owns Eli Lilly stock. Dr. Zuddas has been a consultant to or has received honoraria or grants from EU (FP7 Programme), Angelini, Lundbeck, Janssen, Roche, Servier, Shire, Takeda, and Vifor. Prof. Coghill reports grants and personal fees from Shire, personal fees from Janssen-Cilag, personal fees from Lilly, grants and personal fees from Vifor, personal fees from Novartis, personal fees from Flynn Pharma, personal fees from Medice, and personal fees from Oxford University Press, outside the submitted work. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Abbot, AMGEN, AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Lundbeck, Merck, Otsuka, Pfizer, Roche, Servier, Sumitomo-Dainippon Pharma, Shire, Takeda, Teva, and Schering Plough. Dr Purper-Ouakil has been consultant for Shire, Boiron, and Mensia, and has received honoraria or travel grants from Shire, Otsuka, Medice, Jannssen-Cilag, and Ardix. None of the other authors have any conflicts of interest or disclosures to declare. Part of these data have been included in an FP7 STOP Report to the European Union.
: The study was approved by the Research Ethic Committees (RECs)/Institutional Review Boards (IRBs) of all participating centres.
: Informed consent was obtained from all study participants